Trial Profile
A Phase I Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA BN HER2 (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 25 Jan 2012 Additional lead trial investigator (Olga Bandman) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.